Articles

Results from the CLL11 Study: Salvage Therapy with Obinutuzumab plus Chlorambucil in Patients with CLL and Comorbidities

ASH 2014 – CLL

Dose De-Escalation in Fit, Older Patients with CLL: Balancing Efficacy, Safety, and Tolerability

ASH 2014 – CLL

Update from the RESONATE Trial: Ibrutinib versus Ofatumumab in Relapsed/Refractory CLL

ASH 2014 – CLL

The Benefit of Adding Rituximab to Ibrutinib in Relapsed/Refractory CLL

ASH 2014 – CLL

Interim Analysis of the PROLONG Study: Ofatumumab Maintenance Therapy in Patients with Relapsed CLL

ASH 2014 – CLL

Ibrutinib Salvage in Relapsed CLL After Allogeneic Transplantation

ASH 2014 – CLL

Final Results from the CLL20 Study: Alemtuzumab plus Dexamethasone in Very High–Risk Patients with CLL

ASH 2014 – CLL

Ibrutinib-Based Regimens for Patients with Relapsed/Refractory CLL: Impact of Complex Karyotype

ASH 2014 – CLL

Dose-Ranging Phase 2 Results of Nivolumab Therapy in Metastatic Renal-Cell Carcinoma

ESMO 2014 – Immuno-Oncology

Sequencing Abiraterone Acetate, Cabazitaxel, and Enzalutamide in Post-Docetaxel mCRPC: Exploiting Efficacy and Avoiding Cross-Resistance

ESMO 2014 – Prostate Cancer

Page 138 of 147